文献速递产科母胎医学

产前硫酸镁预防早产儿脑瘫:双盲随机安慰剂对照多中心试验

Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial.
PubMed 文献 · BJOG · 2020-04-29

硫酸镁组与安慰剂组中重度脑瘫粗发生率分别为2.0%和3.3%,校正后OR为0.61(95%CI 0.23-1.65)。结论认为产前硫酸镁可降低孕32周前出生儿童中重度脑瘫的可能性,与其他随机证据一致。

要点

  • 孕32周前有早产风险者产前使用硫酸镁可能降低子代中重度脑瘫风险。
  • 本试验中重度脑瘫校正OR为0.61(95%CI 0.23-1.65),置信区间跨1。
  • 用药方案为负荷量5 g后每小时1 g,对照为等体积安慰剂。

核心结论

  • 产前硫酸镁可降低孕32周前出生儿童发生中重度脑瘫的可能性,结果与相关试验序贯分析汇总的其他随机证据完全一致。

研究设计与样本

  • 孕妇随机接受硫酸镁负荷量5 g后每小时1 g或等体积安慰剂。
  • 儿童在矫正年龄18个月或以上随访,复习病历并使用年龄与发育进程问卷评估。

主要发现

  • 硫酸镁组与安慰剂组中重度脑瘫粗发生率分别为2.0%和3.3%。
  • 硫酸镁组中重度脑瘫的校正比值比低于安慰剂组,OR为0.61(95%CI 0.23-1.65)。
  • 次要结局包括死亡、新生儿疾病、失明和轻度脑瘫。

关键数值与推荐

  • 主要结局指标为中重度脑瘫。
  • 硫酸镁给药方案为负荷量5 g后每小时1 g,安慰剂为相同体积。
  • 随访时间点为矫正年龄18个月或以上。

临床怎么用

  • 对孕32周前有早产风险的孕妇,可考虑产前给予硫酸镁以降低子代中重度脑瘫风险。
  • 用药可参照本试验方案:负荷量5 g后每小时1 g。
  • 目前证据的置信区间较宽,临床决策需结合其他随机证据综合判断。

局限性

  • 中重度脑瘫结局的95%CI为0.23-1.65,跨过无效线,单凭本试验不能确立统计学显著获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the effect of antenatal magnesium sulphate (MgSO4 ) on cerebral palsy (CP) in a manner that also provides adequate power for a linked trial sequential analysis. DESIGN: Double-blind, randomised, placebo-controlled, multi-centre trial. SETTING: Fourteen Danish obstetric departments. POPULATION: In total, 560 pregnant women at risk for preterm delivery before 32 weeks of gestation were randomised from December 2011 to January 2018. Those women gave birth to 680 children. METHODS: Women were randomised to receive either a loading dose of 5 g MgSO4 followed by 1 g/hour or a placebo in identical volumes. The children were followed up at a corrected age of 18 months or older with a review of their medical charts and with the Ages and Stages Questionnaire. MAIN OUTCOME MEASURE: The primary outcome measure was moderate to severe CP. Secondary outcomes included mortality, neonatal morbidity, blindness and mild CP. RESULTS: The crude rates of moderate to severe CP in the MgSO4 group and the placebo group were 2.0% and 3.3%, respectively. The adjusted odds of moderate to severe CP were lower in the MgSO4 group than in the placebo group (odds ratio 0.61; 95% CI 0.23-1.65). CONCLUSIONS: Antenatal MgSO4 before 32 weeks of gestation decreases the likelihood of moderate to severe CP; these results are entirely consistent with other randomised evidence summarised in the linked trial sequential analysis. TWEETABLE ABSTRACT: Antenatal magnesium sulphate may decrease the risk of moderate to severe cerebral palsy in children born before 32 weeks of gestation.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Wolf HT, Brok J, Henriksen TB, et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG. 2020. PMID: 32237024. doi:10.1111/1471-0528.16239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。